Is Neurogene Inc. (NGNE) a Buy, Sell, or Hold?
Neurogene Inc.
NASDAQ:NGNE
$25.43 USD
-$0.37 (-1.43%)
- Volume
- 317.47K
- Average Volume
- 318.71K
- Market Capitalization
- $377.76M
- P/E Ratio
- -6.06
- Dividend Yield
- 0.00%
- Price Target
- $47.50
- Year High
- $74.49
- Year Low
- $12.49
- Payout Ratio
- $0.00
- Current Ratio
- $9.09
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Market |
| CEO | Dr. Rachel L. McMinn Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NGNE |
| CUSIP | 64135M105 |
| CIK | 0001404644 |
| Web | https://www.neurogene.com |
| Phone | (877) 237-5020 |
| Currency | USD |
| Employees | 91 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.09 |
| Quick Ratio | 9.09 |
| Cash Ratio | 4.22 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 408.38 |
| Cash Flow | -4.90 |
| Price / Cash Flow | -4.55 |
| Price / Book | 3.14 |
Price Target and Rating
| Average Stock Price Forecast | $47.50 |
| High Stock Price Forecast | $54.00 |
| Low Stock Price Forecast | $45.00 |
| Forecast Upside/Downside | -46.46% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.83 |
| Trailing P/E Ratio | -6.06 |
| PEG Ratio | 0.29 |
| P/E Growth | 0.29 |
| Net Income | $-36.32M |
| Net Margin | -7689.95% |
| Pretax Margin | -7689.95% |
| Return on Equity | -43.83% |
| Return on Assets | -43.34% |
Financials Score
| AltmanZ Score | 5.83 |
| Piotroski Score | 1.00 |
| Working Capital | 127.85M |
| Total Assets | 164.12M |
| Ebit | -75.79M |
| Market Cap | 377.76M |
| Total Liabilities | 26.71M |
Poll Results
About Neurogene Inc. (NASDAQ:NGNE) Stock
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York. ...
2024-11-28 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
2024-11-27 12:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2024-11-27 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
2024-11-26 16:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2024-11-26 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Frequently Asked Questions
-
What is the current Neurogene Inc. (NGNE) stock price?
-
Neurogene Inc.(NASDAQ:NGNE) stock price is $25.43 in the last trading session. During the trading session, NGNE stock reached the peak price of $74.49 while $12.49 was the lowest point it dropped to. The percentage change in NGNE stock occurred in the recent session was --1.43% while the dollar amount for the price change in NGNE stock was -$-0.37.
-
NGNE's industry and sector of operation?
-
The NASDAQ listed NGNE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NGNE?
-
Ms. Christine Mikail Cvijic J.D. | President, Chief Financial Officer & Corporate Secretary
Mr. Arvind Sreedharan | Senior Vice President of Business Operations
Ms. Donna M. Cochener-Metcalfe J.D. | Senior Vice President & General Counsel
Dr. Julie Jordan M.D. | Chief Medical Officer
Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical & Translational Research -
How many employees does NGNE have?
-
Number of NGNE employees currently stands at 91. NGNE operates from 535 W 24th Street, New York, NY 10011, US.
-
Link for NGNE official website?
-
Official Website of NGNE is: https://www.neurogene.com
-
How do I contact NGNE?
-
NGNE could be contacted at phone #(877) 237-5020 and can also be accessed through its website. NGNE operates from 535 W 24th Street, New York, NY 10011, US.
-
How many shares of NGNE are traded daily?
-
The average number of NGNE shares traded daily for last 3 months was 318.71K.
-
What is the market cap of NGNE currently?
-
The market value of NGNE currently stands at $377.76M with its latest stock price at $25.43